Most diagnostics companies saw increases in share prices compared to last year, resulting in a significant jump in the 360Dx Index.
Gainers in the index outpaced the decliners 19 to nine, and the index outpaced the Dow Jones Industrial Average and Nasdaq Biotechnology Index but lagged the Nasdaq.
Of the 28 companies in the index, 21 companies' share prices increased while the share values of 7 declined month over month.
BD said TRC Capital Investment had made an unsolicited offer to BD shareholders to buy up to 500,000 shares of BD's stock at a price below the current market value.
The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.
Of the 29 companies in the index, 18 companies' share prices declined while the share values of 11 increased month over month.
Of the 29 companies in the index, 16 firms' share prices retreated while the other 13 saw their stock prices rise month over month.
The study said that Cologuard was an "inefficient screening option" for colorectal cancer given its cost as compared to other CRC screening methods.
Of the 27 companies in the index, 14 firms' stocks were down, while 13 companies' share prices increased.
Of the 27 companies in the index, 12 firms' share prices retreated last month, 14 companies' stocks increased, and one firm's share value was flat.